Business
Bio Green Med Solution, formerly Cyclacel Pharmaceuticals, shifted toward protective and fire-safety equipment after 2025 strategic transactions.
Bio Green Med showed no revenue in the comparison row, a narrower loss, heavy stock comp, and a distress Altman-Z screen.
The read at a glance✓ Audited against SEC data
- Business mix — Post-transaction fire-safety equipment companyNote
- Revenue — Comparison row fell to $0Watch
- Losses — Net loss narrowed to $3.0MOK
- Cash — Cash from ops improved to -$4.8MOK
- SBC — Stock comp rose to $2.3MWatch
- Insiders — 0 purchases / 21 salesWatch
- Accounting — Altman-Z distress; other fields unavailableWatch
Where the revenue comes from
Fiscal 2025, as Bio Green Med Solution, Inc. reports it. History and quarterly detail are in the app.
- Product Revenue Fire Safety$747K
- Fire Safety Equipment$603K
- Safety Aparel$119K
- Project Supply And Installation$20K
- Maintenance And Servicing$6K
Leadership changes
From Bio Green Med Solution, Inc.'s own filings, the day they're filed.
- Soon Ping · director · appointmenteff. 2025-09-23
- Mark H. Kirschbaum · Chief Medical Officer · departureeff. 2024-01-25
- Bahasa Melayu · Director · appointment
Latest filings
- 10-Q · Quarterly report2026-08-14
- 8-K · Company announcement2026-08-14
- 8-K · Company announcement2026-07-01
- 8-K · Company announcement2026-06-22
- 8-K · Company announcement2026-06-10
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Bio Green Med Solution, Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.